The central hypothesis being tested in this proposal is that anticoagulant aptamers and their antidotes represent a safe and effective means of controlling coagulation and preventing thrombosis. In the previous funding cycle of this grant, we tested the hypothesis that aptamers are a class of compounds whose activity can be readily reversed by antidotes. We determined that this hypothesis is correct and in the process developed aptamers that can inhibit the activity of several coagulation factors including factors VIIa, IXa, Xa and thrombin, and generated two classes of antidotes, oligonucleotide-based antidotes and universal antidotes, that can rapidly reverse the anticoagulant activity of such aptamers. Furthermore, we also generated aptamer-antidote pairs against the platelet proteins GP IIb/IIIa and VWF and have demonstrated their ability to inhibit platelet function. Thus we now have a set of novel antidote-controllable anticoagulant agents that we will use in this proposal to test the overall hypothesis that such aptamers and antidotes represent a safe and effective approach to control coagulation and platelet function in a variety of clinically relevant settings. Such control is especially valuable in the case of anticoagulant therapy because administration of such therapeutics can induce side effects such as severe bleeding that increase patient morbidity and mortality. Our three specific aims are: 1) to elucidate the mechanism(s) that aptamers utilize to inhibit coagulation factor activity. 2) To assess the net therapeutic benefit of aptamers that inhibit """"""""safe"""""""" anticoagulant targets versus aptamer-antidote pairs that reversibly inhibit """"""""validated"""""""" anticoagulant targets. 3) To determine which anticoagulant aptamers can effectively inhibit coagulation in the setting of cardiopulmonary bypass surgery and determine if oligonucleotide and universal antidotes can rapidly and safely reverse the effects of such aptamers following surgery.

Public Health Relevance

Antithrombotic aptamers and antidotes anticoagulant and/or antithrombotic therapy is required to perform a number of clinical procedures including percutaneous coronary interventions (PCI, """"""""angioplasties""""""""), coronary artery bypass graft (CABG) surgery and other surgeries, as well as dialysis. This therapy is also used as a treatment for a number of thrombotic diseases including acute coronary syndromes (myocardial infarction and unstable angina), deep vein thrombosis, pulmonary embolism, and peripheral vascular disease. The major toxicity and limitation of anticoagulant and antithrombotic therapy is serious drug-induced bleeding. For example, transfusions due to blood loss are required in upwards of 50% of CABG surgeries and 10-15% of PCI procedures. In this grant application, we propose to develop and test a number of new anticoagulant and antiplatelet agents along with antidote molecules for this new therapeutics. We believe the generation of such antidote controllable therapeutic agents will lead to safer treatment of a number of cardiovascular disorders and improve the overall health and welfare of the public.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Kindzelski, Andrei L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Schools of Medicine
United States
Zip Code
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Steen Burrell, K-A; Layzer, J; Sullenger, B A (2017) A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release. J Thromb Haemost 15:1807-1817
Lee, Jaewoo; Jackman, Jennifer G; Kwun, Jean et al. (2017) Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis. Biomaterials 120:94-102
Nimjee, Shahid M; White, Rebekah R; Becker, Richard C et al. (2017) Aptamers as Therapeutics. Annu Rev Pharmacol Toxicol 57:61-79
Toulmé, Jean-Jacques; Giangrande, Paloma H; Mayer, Günter et al. (2017) Aptamers in Bordeaux, 24-25 June 2016. Pharmaceuticals (Basel) 10:
Woodruff, R S; Ivanov, I; Verhamme, I M et al. (2017) Generation and characterization of aptamers targeting factor XIa. Thromb Res 156:134-141
Sullenger, Bruce A; Nair, Smita (2016) From the RNA world to the clinic. Science 352:1417-20
Nimjee, Shahid M; Povsic, Thomas J; Sullenger, Bruce A et al. (2016) Translation and Clinical Development of Antithrombotic Aptamers. Nucleic Acid Ther 26:147-55
Kahsai, Alem W; Wisler, James W; Lee, Jungmin et al. (2016) Conformationally selective RNA aptamers allosterically modulate the ?2-adrenoceptor. Nat Chem Biol 12:709-16
Soule, Erin E; Bompiani, Kristin M; Woodruff, Rebecca S et al. (2016) Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant. Nucleic Acid Ther 26:1-9

Showing the most recent 10 out of 30 publications